Newsbenzinga
Top Wall Street Forecasters Revamp Regeneron Pharmaceuticals Expectations Ahead Of Q3 Earnings
· Published
Article summary
Regeneron expects Q3 EPS of $16.19 and revenue of $4.56B; extended BARDA’s Inmazeb supply deal as analysts raise price targets.
An excerpt from the original article.
Comments —
Loading comments…